At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 548 enrolled

Drug / intervention

Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant +4 morebiological

Likely dose

Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant 0.5 mLfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00952276

NCT00952276Phase 2Completed

Compare CT.gov

Immunogenicity and Safety of Multiple Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects

Sanofi·interventional·Posted Aug 6, 2009·Updated Oct 3, 2011

In Brief

A Phase 2 clinical trial evaluating Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant, Monovalent Subvirion A/H1N1 influenza vaccine, and 1 other intervention for Influenza and Swine-origin A/H1N1 Influenza. Completed, enrolled 548 participants across 15 sites.

Detailed Summary

The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after a single injection. * To describe the safety of the candidate vaccines after a single injection.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsInfluenza, Swine-origin A/H1N1 Influenza

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

20102011201220132014201520162017201820192020202120222023202420252026

First PostedAug 2009

Enrollment StartOct 2009

Primary CompletionDec 2010

Study CompletionMar 2011

TodayJul 2026

First PostedAug 6, 2009

Enrollment StartOct 1, 2009

Primary CompletionDec 1, 2010

Study CompletionMar 1, 2011

TodayJul 2, 2026

Enrollment to primary: 1.2 yearsPosted 16.9 years ago